Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
CAB-AXL-ADC Safety and Efficacy Study in Adults With NSCLC
NCT04681131 · View on ClinicalTrials.gov ↗
Study Summary
The objective of this study is to assess safety and efficacy of CAB-AXL-ADC in NSCLC
Conditions Studied
Interventions
- BIOLOGICAL PD-1 inhibitor
- BIOLOGICAL CAB-AXL-ADC
Study Locations (20)
California
- City of Hope - Duarte — Duarte
- University of California Irvine Medical Center (UCIMC) - Chao Family Comprehensive Cancer Center — Irvine
- California Research Institute — Los Angeles
- USC Norris — Los Angeles
- Cedars-Sinai — Los Angeles
- University of California, San Diego (UCSD) - Moores Cancer Center — San Diego
- American Institute of Research — Whittier
Florida
- Florida Cancer Specialists & Research Institute — Fleming Island
- Florida Cancer Specialists & Research Institute — Fort Myers
- Florida Cancer Specialist — St. Petersburg
- Moffitt Cancer Center — Tampa
- Florida Cancer Specialists — West Palm Beach
Kentucky
- Baptist Health Systems — Lexington
- University of Kentucky — Lexington
- Norton Cancer Institute, Brownsboro Hospital Campus — Louisville
Colorado
- University of Colorado Anschutz Medical Campus — Aurora
Georgia
- Augusta University - Georgia Cancer Center — Augusta
Louisiana
- Hematology/Oncology Clinic — Baton Rouge
Massachusetts
- Dana-Farber Cancer Institute — Boston
Michigan
- University of Michigan Comprehensive Cancer Center — Detroit
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 85 participants |
| Start Date | 2021-03-17 |
| Est. Completion | 2025-07-09 |
| Phase | Phase 2 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04681131
The ClinicalTrials.gov registry entry for NCT04681131 describes a study currently listed as completed. It is categorized as Phase 2, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 85 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is BioAtla, which has 4 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 1 condition, with Non-Small-Cell Lung Cancer appearing as the primary indexed condition, and to 2 interventions — of which PD-1 inhibitor is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT04681131 reports 20 study locations spanning 8 distinct geographic areas — top geographies include California, Florida, Kentucky. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT04681131 about?
NCT04681131 is a clinical study titled "CAB-AXL-ADC Safety and Efficacy Study in Adults With NSCLC". The objective of this study is to assess safety and efficacy of CAB-AXL-ADC in NSCLC
What is the current status of trial NCT04681131?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 85 participants. The study started on 2021-03-17. Estimated completion is 2025-07-09.
What conditions does trial NCT04681131 study?
This clinical trial studies the following conditions: Non-Small-Cell Lung Cancer. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT04681131?
The interventions under investigation include: PD-1 inhibitor (BIOLOGICAL), CAB-AXL-ADC (BIOLOGICAL). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT04681131?
This trial is sponsored by BioAtla, which has 4 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT04681131 being conducted?
This trial has 20 study locations across California, Colorado, Florida, Georgia, Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.